Abstract 12476: Dapagliflozin versus Empagliflozin and the Risk for Cardiovascular Outcomes in Patients With Type 2 Diabetes: A Nationwide Population-Based Study
Abstract
Introduction:
Dapagliflozin and empagliflozin are the two most widely used sodium-glucose co-transporter 2 inhibitors (SGLT2i) for type 2 diabetes (T2DM) worldwide. The study was conducted to compare the cardiovascular outcomes of two SGLT2i, dapagliflozin and empagliflozin.
Methods:
We conducted a nationwide cohort study using the Korean National Health Insurance Service database and an active-comparator new-user design. Patients newly prescribed either dapagliflozin or empagliflozin between 2016 and 2018 for T2DM were retrospectively analyzed and matched in a 1:1 ratio based on propensity scores estimated using 53 potential confounding variables. The primary outcome was major adverse cardiovascular events (MACE), which is a composite of myocardial infarction, ischemic stroke, heart failure (HF) events (i.e., hospitalization for HF or HF-related death), and cardiovascular death. Secondary outcomes were HF events, cardiovascular death, and all-cause mortality.
Results:
A total of 145,502 patients were included in the final analysis (mean age 57±12 years, 57% male). During mean follow-up of 2.1±0.7 years, there was no significant difference in the incidence of MACE between the two groups (incidence rate 6.95 vs. 7.33 per 1000 person-years). The hazard ratio [HR] for dapagliflozin to empagliflozin users was 0.95 (95% confidence interval [CI] 0.87-1.03; P= 0.199). Regarding secondary outcomes, however, compared with empagliflozin users, dapagliflozin users had a lower risk of…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 145,502 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.